Home Itens selecionados Provedores de dados OAI Créditos Sobre Ajuda

			Busca avançada
	Provedor de dados BJMBR (1) Ciência Rural (1) Autor Amorim,Renée Laufer (1) Batista,Aline Carvalho (1) Brito,Luiz Augusto Batista (1) Croce,Giuliana Brasil (1) Damasceno,Adilson Donizeti (1) Faleiro,Mariana Batista Rodrigues (1) Gurgel,D.C. (1) Mattos,T.V. Arruda (1) Morais,C.E. (1) Moura,Veridiana Maria Brianezi Dignani de (1) Rodrigues,Marcela Marcondes Pinto (1) Silva,A.V. Alves da (1) Tavora,F. (1) Teixeira,A.C. (1) Toledo,Denise Caroline (1) Mais... Palavra-chave Prostatic carcinoma (2) Benign prostatic hyperplasia (1) Biomarker (1) Dog (1) ERG expression (1) Gelatinases (1) PTEN (1) Proliferative inflammatory atrophy (1) Prostatic intraepithelial neoplasia (1) Radical prostatectomy (1) Mais... Tipo do documento Info:eu-repo/semantics/article (2) Ano 2019 (1) 2013 (1) País Brazil (2) Idioma Inglês (2)		Ordenar por:  Relevância Autor Título Ano Registros recuperados: 2 Primeira ... 1 ... Última Prevalence of ERG expression and PTEN loss in a Brazilian prostate cancer cohort BJMBR Morais,C.E.; Gurgel,D.C.; Teixeira,A.C.; Mattos,T.V. Arruda; Silva,A.V. Alves da; Tavora,F.. PTEN is the most commonly inactivated tumor suppressor gene in primary prostate cancer (PCa) and its loss is associated with poor clinical outcomes. ERG rearrangement is a genomic alteration frequently found in PCa and its prognostic significance has yielded mixed results. Although the association of PTEN and ERG biomarkers has potential impact on clinical outcomes, studies examining the two genes simultaneously are scarce in Brazilian populations. In this study, we retrospectively examined the relationship between ERG expression and PTEN loss in 119 surgically treated prostate cancer patients from Northeastern Brazil through immunohistochemical analysis. ERG expression was found in 41.0% (48/117) of cases and the loss of PTEN detected in 38.1% (40/105) of... Tipo: Info:eu-repo/semantics/article Palavras-chave: ERG expression; PTEN; Biomarker; Radical prostatectomy; Prostatic carcinoma. Ano: 2019 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2019001200610 Matrix metalloproteinases 2 and 9 expression in canine normal prostate and with proliferative disorders Ciência Rural Faleiro,Mariana Batista Rodrigues; Croce,Giuliana Brasil; Toledo,Denise Caroline; Rodrigues,Marcela Marcondes Pinto; Batista,Aline Carvalho; Damasceno,Adilson Donizeti; Brito,Luiz Augusto Batista; Amorim,Renée Laufer; Moura,Veridiana Maria Brianezi Dignani de. In this study the expression of metalloproteinases 2 (MMP-2) and 9 (MMP-9) in canine normal prostates and with proliferative disorders was evaluated to verify the role of these enzymes in extracellular matrix remodeling (ECM) and in the tissue invasion process. A total of 355 prostatic samples were obtained, from which 36 (10.1%) were normal prostates, 46 (13.0%) with benign prostatic hyperplasia (BPH), 128 (36.1%) with proliferative inflammatory atrophy (PIA), 74 (20.8%) with prostatic intraepithelial neoplasia (PIN), and 71 (20.0%) with prostatic carcinoma (PC). Difference in cytoplasmic immunohistochemical staining of MMP-2 and MMP-9 between acinar epithelium and periacinar stroma was found regarding the different diagnosis. The correlation between... Tipo: Info:eu-repo/semantics/article Palavras-chave: Dog; Gelatinases; Benign prostatic hyperplasia; Proliferative inflammatory atrophy; Prostatic intraepithelial neoplasia; Prostatic carcinoma. Ano: 2013 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0103-84782013000600015 Registros recuperados: 2 Primeira ... 1 ... Última

Empresa Brasileira de Pesquisa Agropecuária - Embrapa Todos os direitos reservados, conforme Lei n° 9.610 Política de Privacidade Área restrita		Embrapa Parque Estação Biológica - PqEB s/n° Brasília, DF - Brasil - CEP 70770-901 Fone: (61) 3448-4433 - Fax: (61) 3448-4890 / 3448-4891 SAC: https://www.embrapa.br/fale-conosco